Acute localised exanthematous pustulosis secondary to pembrolizumab

Australas J Dermatol. 2017 Nov;58(4):322-323. doi: 10.1111/ajd.12594. Epub 2017 Jul 10.

Authors

Charlie Y Wang¹, Christine Khoo², Chris J McCormack³, Wen Xu⁴, Yan Pan^{3

5}

Affiliations

¹ Monash University, Melbourne, Victoria, Australia.
² Department of Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Department of Dermatology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁵ Victorian Melanoma Service, The Alfred Hospital, Melbourne, Victoria, Australia.

PMID: 28691194
DOI: 10.1111/ajd.12594

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Generalized Exanthematous Pustulosis / etiology*
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Humans
Male
Melanoma / drug therapy*
Melanoma / secondary
Middle Aged
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab